In 2025, CR Pharma conducted an environmental assessment and disclosed corporate waste management data in accordance with recognized sustainability reporting standards.The company provided a breakdown of its waste by type (hazardous vs non-hazardous) and treatment method (recovery vs disposal), enabling greater transparency into its waste handling and environmental practices.
| Metric (tonnes) | 2025 | 2024 | 2023 | 2022-2019 |
|---|---|---|---|---|
Total Waste Generated | 248,469.35a | 183,567.87a | 160,060.02a | |
Total Waste Recovered | 231,628.21a | 150,663.09a | 143,636.21a | |
Total Hazardous Waste Generated | 8,217a | 4,947a | 5,107.62a | |
Non-Hazardous Waste Disposed | N/A | N/A | N/A |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.
In 2025, CR Pharma generated a total of 248,469metric tonnes of waste.a
Of this amount, 93.22% of CR Pharma's total waste generated was recovered through methods such as recycling, reuse, or composting, while 6.78% was disposed of through landfilling, incineration, or combustion.a
In 2025, CR Pharma reported a total waste generation of 248,469 metric tonnes, of which 93.22% was recovered through recycling, reuse, or composting.This high recovery rate suggests that CR Pharma has implemented strong circular economy practices and actively prioritizes sustainable waste management.a
Since 2023, CR Pharma's total waste generation increased by 55.24%, including a 35.36%increase in 2025, indicating a persistent upward trend that may reflect scaling operations, inefficiencies in resource use, or a lack of effective waste minimization practices.a
Over the same period, CR Pharma's waste recovery rate increased by 3.88%, including a 13.58% rise in 2025, indicating growing emphasis on circularity and improved operational practices for diverting waste from disposal.a
Overall, CR Pharma has seen a consistent rise in waste generation both over the long term and in the year 2025. However, the company has also steadily improved its waste recovery performance, suggesting that it is actively working to offset the environmental consequences of increased production through enhanced circularity efforts.
In 2025, CR Pharma generated a total of 248,469 metric tonnes of waste.a
Of this amount, 3.31% of CR Pharma's total waste generated of was classified as hazardous waste, characterized by properties such as toxicity, flammability, corrosiveness, or reactivity that may pose risks to human health, ecosystems, or the environment.96.69% was identified as non-hazardous waste, generally considered less harmful and subject to lighter regulatory controls.a
Since 2023, CR Pharma's total waste generation increased by 55.24%, including a 35.36% rise in 2025, reflecting a persistent upward trend that could be linked to operational growth, inefficient material use, or limited investment in waste prevention systems.a
Over the same period, the share of hazardous waste in CR Pharma's total output increased by 3.63%, including a further 22.71% rise in 2025, suggesting a troubling upward shift toward more environmentally harmful waste streams that could raise compliance costs and environmental risks.a
Overall, CR Pharma has seen a continuous rise in both total waste and hazardous waste over time, signaling a worsening environmental impact that may require urgent reassessment of material sourcing, production processes, or waste mitigation strategies.a